Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background: Vilazodone is the latest US Food and Drug Administration approved antidepressant agent available in the USA. Its putative mechanism of antidepressant action enhances the release of serotonin across the brain’s serotonergic pathways specifically by inhibiting the serotonin transporter, similar to a selective serotonin reuptake inhibitor (SSRI), and simultaneously stimulating serotonin-1a receptors via partial agonism, similar to the anxiolytic buspirone. This combined activity in the single vilazodone agent has been termed by the authors as being a serotonin partial agonist and reuptake inhibitor or (SPARI). Methods: A MEDLINE and Internet search was conducted and the resultant preclinical and clinical evidence was reviewed . The authors attempt to review laboratory data, animal model data and human trial data to develop a translational theory on the mechanism of antidepressant action of this agent and also its adverse effect potential. Results: Randomized, controlled empirical data for vilazodone have gained it approval for treating major depressive disorder. It combines two well known pharmacodynamic mechanisms of serotonergic action into a novel agent. Although no head-to-head studies against other antidepressants have been published, the efficacy data for vilazodone appear comparable to other known antidepressants, with similar gastrointestinal side effects to SSRI or serotonin norepinephrine reuptake inhibitor (SNRI) antidepressants, but possibly with a lower incidence of sexual side effects and weight gain. Discussion: Vilazodone will lend itself to the current armamentarium in the treatment of major depressive disorder and may hold promise for patients who cannot tolerate other antidepressants. Its unique SPARI mechanism of action could also be efficacious for patients who do not respond to SSRI or SNRI antidepressant monotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002 · cited 1×
“In fact, the STAR*D trial studied patients who did not respond to treatment with citalopram, comparing augmentation with either buspirone or with bupropion sustained release, and found no significant differences in remission rates between these two combination treatments [Trivedi et al. 2006].”
ResultAnxiogenic stimuli in the elevated plus-maze
Treit, D., Menard, J., & Royan, C. (1993) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(93)90492-c · Cited by 628
Blier, P., Ward, H. E., Tremblay, P., Laberge, L., Hébert, C., & Bergeron, R. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09020186 · Cited by 316 · cited 2×
“…neuromodulation [Schwartz, 2010], clinicians have resorted to higher levels of rational polypharmacy in order to gain full remission when monotherapies fail by using combination drug treatment earlier and earlier in treatment selection [Blier et al. 2010; Rush, 2010; Schwartz and Rush, 2007].”
BackgroundA comparison of anxiolytic and nonanxiolytic agents in the shock-probe/burying test for anxiolytics
Treit, D. (1990) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(90)90151-7 · Cited by 86 · cited 2×
“…suggestive of a potential rapid onset ADT [Page et al. 2002; Bartoszyk et al. 1997] in that rodent vocalization, forced swim test, elevated maze, and predator-induced stress models appeared positive for antidepressant effects [Adamec et al. 2004; Treit et al. 1993; Treit, 1990; Pellow et al. 1985].”
BackgroundStahl, S. M. (2010) · CNS Spectrums · doi:10.1017/s1092852900027334 · Cited by 40 · cited 1×
“…for vilazodone, a single monotherapy agent like vilazodone that combines the same pharmacologic actions as the combination of an SSRI with buspirone would be able to provide the potential efficacy benefits of this combination, particularly if administered early in treatment [Stahl, 2010, 2009].”
BackgroundSelf-citation
Research works printed but not linked: 29
- 10.1016/j.ejphar.2004.09.009 · DOI
- APA, 2000, American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 4th edn text revision
- APA, 2010, Am J Psychiatry, 150, 1
- Barowsky J., 2006, Psychiatry (Edgmont), 3, 42
- 10.1016/S0014-2999(96)00999-5 · DOI
- 10.4088/JCP.v67n0514 · DOI
- 10.1111/j.1755-5949.2008.00067.x · DOI · Paper page
- 10.1038/sj.bjp.0703496 · DOI
- 10.1021/jm040793q · DOI · Paper page
- 10.1016/j.pbb.2003.09.020 · DOI
- Hudziak J., 2005, Buspirone
- 10.1016/j.ejphar.2005.01.018 · DOI
- Khan, A., Cutler, A.J., Kajdasz, D.K., Gallipoli, S, Athanasiou, M, Robinson, D.S. et al . (2011) A Randomized, Double-Blind, Placebo-Controlled, 8-Week Study of Vilazodone, a Serotonergic Agent for the Treatment of Major Depressive Disorder. J Clin Psychiatry 72: 441–447. · DOI · Paper page
- 10.1007/s002130100703 · DOI
- Othmer E., 1987, J Clin Psychiatry, 48, 201
- 10.1124/jpet.102.034280 · DOI
- 10.1016/0165-0270(85)90031-7 · DOI · Paper page
- Pies R., 1998, Handbook of Essential Psychopharmacology
- 10.1016/S0969-8051(00)00120-7 · DOI
- 10.4088/JCP.08m04637 · DOI · Paper page
- 10.1016/j.ejphar.2005.05.039 · doi:10.1016/j.ejphar.2005.05.039
- 10.1176/appi.ajp.2009.09121768 · DOI
- Schwartz T.L., 2007, P&T, 32, 28
- Schwartz T.L. and Stah, S.M. (2010) Optimizing Antidepressant Management of Depression: current Status and Future Perspectives Vol. 27, 9th edn. Basel: Karger, 254–267. · DOI
- 10.1358/dof.2001.026.03.611242 · DOI
- Stahl S., 2008, Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 3rd edn
- 10.4088/JCP.09bs05697blu · DOI
- Stahl S., 2011, Essential Psychopharmacology: the Prescriber's Guide, 4th edn
- 10.1017/S1092852900020307 · DOI · Paper page
Cited by
Serotonergic Drugs for Depression and Beyond
M. Stahl, S., Lee-Zimmerman, C., Cartwright, S., & Ann Morrissette, D. (2013) · Current Drug Targets · doi:10.2174/1389450111314050007 · Cited by 272
Antidepressant efficacy and side-effect burden: a quick guide for clinicians
Santarsieri, D., & Schwartz, T. (2015) · Drugs in Context · doi:10.7573/dic.212290 · Cited by 224
“Abbreviations: ADT, antidepressant treatment; DLPFC, dorsolateral prefrontal cortex; ECT, electroconvulsive therapy; FDA, Food and Drug Administration; GI, gastrointestinal; HAM-D, Hamilton Rating Scale for Depression; ITT, intentto-treat; MADRS, Montgomery–Asberg Depression Rating Scale; MAOI, monoamine oxidase inhib…”
InfluentialSelf-citationMontejo, A. L., Montejo, L., & Baldwin, D. S. (2018) · World Psychiatry · doi:10.1002/wps.20509 · Cited by 189
Jing, E., & Straw-Wilson, K. (2016) · Mental Health Clinician · doi:10.9740/mhc.2016.07.191 · Cited by 121
“Vilazodone is an SSRI and a 5HT1A receptor partial agonist.(27) Vilazodone is presumed to have less risk for sexual side effects because of its partial activity at the 5HT1A receptors.”
Pharmacotherapy for Anxiety Disorders.
O’Leary, K. B., & Khan, J. S. (2024) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2024.04.012 · Cited by 22
Metadata
- Authors
- Schwartz, T. L., Siddiqui, U. A., & Stahl, S. M.
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2011-05-31
- Volume
- 1
- Issue
- 3
- Pages
- 81-87
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- OpenAlex
- W2046233567
- Cited by
- 55
- References
- 6
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor. https://app.cochat.ai/papers/10.1177/2045125311409486
- The paper
- Schwartz, T. L., Siddiqui, U. A., & Stahl, S. M. (2011). Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/2045125311409486
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.